Skip to main content Accessibility help

Sacubitril/Valsartan: potential treatment for paediatric heart failure

  • Bibhuti B. Das (a1), Frank Scholl (a1), Breanna Vandale (a1) and Maryanne Chrisant (a1)


The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.


Corresponding author

Author for correspondence: B. B. Das, MD, FAAP, FACC, Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, 1150 North 35 Avenue, Hollywood, FL 33021, USA. E-mail:


Hide All

Cite this article: Das BB, Scholl F, Vandale B, Chrisant M. (2018) Sacubitril/Valsartan: potential treatment for paediatric heart failure. Cardiology in the Young 28: 1077–1081. doi: 10.1017/S104795111800080X



Hide All
1. Kirk, R, Dipchand, AI, Rosenthal, DN, et al. The international Society of Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: Executive summary. J Heart Lung Transplant 2014; 33: 888909.
2. Rosenthal, D, Chrisant, M, Edens, E, et al. International Society of Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transpl 2004; 23: 13131333.
3. Lipshultz, SE, Sleeper, LA, Towbin, JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 24: 16471655.
4. Nugent, AW, Daubeney, PE, Chondros, P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 16391646.
5. Andrew, RE, Fenton, MJ, Ridout, DA, Burch, M. New-onset heart failure due to heart muscle disease in childhood: a prospective study in United Kingdom and Ireland. Circulation 2008; 117: 7984.
6. Dipchand, AI, Kirk, R, Edwards, LB, et al. The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report-2013; focus theme: age. J Heart Lung Transpl 2013; 32: 979988.
7. Rossano, JW, Shaddy, RE. Heart failure in children: etiology and treatment. J Pediatr 2014; 165: 228233.
8. Sipido, KR, Eisner, D. Something old, something new: changing views on the cellular mechanism of heart failure. Cardiovasc Research 2005; 68: 167174.
9. Scoote, M, Poole-Wilson, PA, Williams, AJ. The therapeutic potential of new insights into myocardial excitation-contraction coupling. Heart 2003; 89: 371376.
10. Kantor, PF, Lougheed, J, Dancea, A, et al. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Can J Cardiol 2013; 29: 15351552.
11. Krum, H, Shi, H, Pitt, B, et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy; analysis of the EMPHASIS-HF study. Circ Heart Fail 2013; 6: 711718.
12. Das, BB, Solinger, R. Role of natriuretic peptide family in cardiovascular medicine. Cardiovasc Hematol Agents Med Chem 2009; 7: 2942.
13. Nagaya, N, Satoh, T, Nishikimi, T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000; 101: 498503.
14. Knecht, M, Pagel, I, Langenickel, T, et al. Increased expression of neural neutral endopeptidase in severe heart failure. Life Sci 2002; 71: 27012712.
15. Braunwald, E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Col Card 2015; 65: 10291041.
16. Goldsmith, S. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep 2004; 1: 4550.
17. Packer, M, Califf, RM, Konstam, MA, et al. Comparison of Omapatrilat versus Enalapril randomized trial of utility in reducing events (OVERTURE). Circulation 2002; 106: 920926.
18. Cohn, JN, Tognoni, G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 16671675.
19. McMurray, JV, Packer, M, Desai, AD, et al. Angiotensin-Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 9931004.
20. Desai, AS, McMurray, JJV, Milton, P, et al. Effects of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 19901997.
21. Patel, MD, Mohan, J, Schneider, C, et al. Pediatric and adult dilated cardiomyopathy represent distinct pathological entities. JCI Insight 2017; July 20: 2: 94382.
22. Miyamoto, SD, Stauffer, BL, Nakuno, S, et al. Beta-adrenergic adaptation in pediatric idiopathic dilated cardiomyopathy. Eur Heart J 2012; 35: 19.
23. Nakano, SJ, Sucharov, J, van Dusen, R, et al. Cardiac adenylyl cyclase and phosphodiesterase expression profiles vary by age, disease, and chronic phosphodiesterase inhibitor treatment. J card fail 2017; 23: 7280.
24. Shaddy, RE, Boucek, MM, Hsu, DT, et al. Carvedilol for children and adolescent with heart failure: a randomized controlled trial. J Am Med Assoc 2007; 298: 11711179.
25. Almond, CSD, Thiagrajan, RR, Piercey, GE, et al. Waiting list mortality among children listed for heart transplantation in children in the United States. Circulation 2009; 5: 717727.
26. International Society of Heart and Lung Registry Data. J Heart Lung Transplant 2017; 36: 10371079.
27. Packer, M, McMurray, JJV, Desai, AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015; 131: 5461.
28. Solomon, SD, Rizkala, AR, Gong, J, et al. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail 2017; 7: 471482.
29. Ruilope, LM, Dukat, A, Bohm, M, et al. Blood-pressure reduction with LCZ696, a novel dual acting inhibitor of the angiotensin II receptor and neprilysin: a randomized, double-blinded, placebo-controlled, active comparator study. Lancet 2010; 375: 12551266.
30. Ponikowski, P, Voors, A, Anker, S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2016; 74: 891975.
31. Yancy, C, Jessup, M, Bozkurt, B, et al. 2017 ACC/AHA/HSFA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guidelines for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2017; 23: 776803.
32. Shaddy, R, Canter, C, Halnon, N, et al. Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left heart ventricle systolic dysfunction. Am Heart J 2017; 193: 2334.



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed